BPC-157 (5mg)

Chick chorioallantoic membrane and endothelial tube-formation assays showed that BPC-157 increased vessel density and sped blood-flow recovery in ischemic hindlimb muscle of rats.^[2] The same paper reported higher vascular endothelial growth factor receptor 2 (VEGFR2) expression and time-dependent activation of VEGFR2-Akt-eNOS signaling, which is tied to nitric-oxide-mediated endothelial function.^[2]

If you are running a VEGFR2 or nitric-oxide-synthase readout in endothelial cells, this is the usual citation.

In cultured rat Achilles tendon fibroblasts, BPC-157 sped ex vivo tendon-explant outgrowth, raised cell survival under oxidative (H2O2) stress, and increased fibroblast migration in transwell assays in a dose-dependent way.^[3] The migratory effect tracked with higher phosphorylation of focal adhesion kinase (FAK) and paxillin, proteins involved in cytoskeletal reorganization and cell adhesion. Total protein levels did not change.^[3]

Tendon-repair designs often put BPC-157 next to bFGF or EGF as growth-factor controls. Combined tissue-repair protocols also run it with TB-500.

A cDNA microarray of BPC-157-treated tendon fibroblasts listed growth hormone receptor (GHR) among the most strongly up-regulated genes.^[4] Follow-up assays showed dose- and time-dependent rises in GHR mRNA and protein. When the authors then added exogenous growth hormone to those pretreated cultures, the JAK2 pathway activated and fibroblast proliferation went up.^[4]

Japjec et al. surgically cut the quadriceps myotendinous junction in rats, an injury that does not heal on its own. Intraperitoneal and oral BPC-157 regimens were both tied to full functional recovery, reversal of progressive muscle atrophy, and structural closure of the defect by postoperative day 42.^[5]

A 2025 systematic review of 36 studies (35 preclinical, 1 clinical) reported that BPC-157 changes growth hormone receptor expression plus angiogenic and inflammatory-cytokine pathways in animal muscle, tendon, ligament, and bone injury models. The authors also said the evidence base is still mostly preclinical (level IV-V).^[8]

BPC-157 was first described in work on cytoprotective compounds from gastric juice. A lot of the early papers are rat ulcer, fistula, and mucosal-injury models.^[1] Reviews report protective findings across those GI-injury models, in part through the nitric-oxide system and several neurotransmitter pathways. The upstream mechanism is still not fully worked out.^[1]

Most synthetic peptides longer than 8–10 amino acids lose most of their activity when given by mouth. Gastric acid and digestive proteases break down the backbone before much intact peptide reaches circulation. BPC-157 is a documented exception. The sequence is a stabilized fragment of a native human gastric-juice protein, and review papers report it stays structurally intact in human gastric juice for more than 24 hours in vitro.^[1][12] That is why oral gavage and drinking-water protocols show up next to injectable routes in this literature.

Head-to-head route comparisons inside a single study are rare. One 2008 rat colocutaneous-fistula paper is the cleanest example: BPC-157 was given either continuously in drinking water or once daily by intraperitoneal injection at matched doses (10 µg/kg or 10 ng/kg). Fistula closure was scored macroscopically, microscopically, biomechanically, and functionally over 28 days.^[11] Both routes sped healing of the colonic and skin defects to a similar degree. The dissected-quadriceps model above showed the same pattern for a musculoskeletal endpoint: intraperitoneal and oral regimens were both tied to full functional recovery.^[5]

Neither study measured comparative bioavailability. No controlled human pharmacokinetic study has quantified how much intact peptide reaches circulation after oral dosing. Comparable outcomes in those two rodent protocols do not mean the routes are interchangeable across endpoints, species, or doses.

Oral and intragastric dosing fits BPC-157's original GI-tract context: the peptide hits the luminal mucosa directly, and you avoid injection-site trauma that can confound skin- or gut-healing designs. Injection (IP/SC/IM) is still the default in the receptor and growth-factor papers cited above, because it skips the GI tract and delivers a known, individually controlled dose. That oral stability has not been documented for TB-500, which Tetrava also sells for combined tissue-repair protocols. Pick the route that matches the protocol. Tetrava Labs sells BPC-157 as a lyophilized vial for injectable research solutions and as BPC-157 capsules for oral-route protocols.

One published study gave intraperitoneal BPC-157 in a mouse falling-weight traumatic brain injury (TBI) model.^[6] Treated mice had lower 24-hour post-injury mortality and less severe hemorrhage and edema on gross and histological exam. Outcomes were better when the peptide was given before injury.^[6] That is still the only direct TBI dataset we found. Do not stretch it past one study and one species.

A common misconception is that the large rodent and cell-culture literature on BPC-157 equals demonstrated human efficacy. The reviews do not support that.

• BPC-157 is not approved by the FDA or any comparable regulator for human therapeutic use, and it is prohibited by major anti-doping authorities in professional sports.^[8]
• Human data are limited to a handful of pilot-level, non-blinded studies. One retrospective case series of intra-articular injection for chronic knee pain reported that 14 of 16 patients had relief beyond six months.^[7]
• A 2025 systematic review found only one clinical-level study among 36 included papers, and no published in-human safety data, even though preclinical toxicology looked favorable.^[8]
• A 2025 narrative review called BPC-157 investigational and asked for well-designed human trials before anyone extrapolates from animal data into the clinic.^[9]

Tetrava Labs ships BPC-157 as a lyophilized powder so it stays stable in transit. Store sealed vials at -20°C. Do not freeze-thaw them over and over. Reconstitute under sterile technique with a protocol-appropriate diluent right before use. For compound context and handling notes, see BPC-157 vs TB-500.

Once reconstituted, keep working solutions at 4°C and use them inside the window in your laboratory SOP. Record diluent lot, reconstitution date, and operator in the ELN so prep conditions stay auditable next to the batch Certificate of Analysis.